Skip to content
DataLookout
Menu

NCT07801495

A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below.

  1. Minor Study sites: 2 to 3
  2. Minor Study sites: 1 to 2
  3. Notable Recruitment opened
    • Study sites: 0 to 1
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Part A: Number of participants achieving American College of Rheumatology 50 (ACR50) response
Timeframe: Week 12
Part A and B: Number of participants achieving American College of Rheumatology 50 (ACR50) response
Timeframe: Week 12

Secondary (2)

Part B: Number of participants achieving American College of Rheumatology 50 (ACR50) response
Part A and Part B: Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

Arms and interventions

Part A: DDY391-Schedule 1 Dose AExperimental

Participants will receive DDY391 Schedule 1 Dose A.

Part A: Placebo Schedule 1Placebo comparator

Participants will receive matching placebo Schedule 1.

Part B: DDY391- Schedule 1 Dose AExperimental

Participants will receive DDY391 Schedule 1 Dose A. Based on treatment response, participants will then either continue receiving DDY391 or switch to local standard of care (SOC).

Part B: DDY391- Schedule 1 Dose BExperimental

Participants will receive DDY391 Schedule 1 Dose B. Based on treatment response, participants will then either continue receiving DDY391 or switch to local SOC.

Part B: DDY391- Schedule 1 Dose CExperimental

Participants will receive DDY391 Schedule 1 Dose C. Based on treatment response, participants will then either continue receiving DDY391 or switch to local SOC.

Part B: Placebo Schedule 1Experimental

Participants will receive matching placebo Schedule 1. Based on treatment response, participants will then either switch to DDY391 Schedule 1 Dose A or receive local SOC.

Part B: DDY391- Schedule 2 Dose CExperimental

Participants will receive DDY391 Schedule 2 Dose C. Based on treatment response, participants will then either switch to DDY391 Schedule 1 Dose A or receive local SOC.

Part B: Placebo Schedule 2Experimental

Participants will receive matching placebo Schedule 2. Based on treatment response, participants will then either switch to DDY391 Schedule 1 Dose A or receive local SOC.

Drugs: DDY391, Placebo

Sites

3 sites in 1 country